(E)-4-Imidazol-1-yl-but-2-enylamine | 93668-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-4-Imidazol-1-yl-but-2-enylamine
• 英文别名: 4-Imidazol-1-ylbut-2-en-1-amine
• CAS: 93668-02-1
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: CSIGJYXNUMZBBX-UHFFFAOYSA-N

物化性质

• 沸点：
  331.7±35.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氯-2-酰氯噻吩 、 (E)-4-Imidazol-1-yl-but-2-enylamine 在 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 以57%的产率得到5-Chloro-N-[4-(1H-imidazol-1-yl)-2-butenyl]-2-thiophene carboxamide
  参考文献：
  名称：

  Thromboxane synthetase inhibitors and antihypertensive agents. 3. N-[(1H-imidazol-1-yl)alkyl]heteroaryl amides as potent enzyme inhibitors

  摘要：

  The title compounds were prepared as the heterocyclic analogues of thromboxane (TX) synthetase inhibitors and antihypertensive agents previously reported from our laboratories. These compounds were at least as active TX synthetase inhibitors as their benzene isosteres with the indole derivatives 50-55 having the most potent enzyme inhibiting activity measured to date in our laboratories. The best compound, 54, is more than 200-fold more potent than the standard, dazoxiben. In contrast, the antihypertensive activity of these series of compounds was no better than their benzene counterparts and is far lower than the isoindoledione derivatives prepared in a related series. The structure-activity relationship results from this study were similar to our previous observations and include the fact that the amide moiety effectively replaces a carboxylic acid for potent TX synthetase inhibition and that a four to six methylene unit separation (approximately 8.5 A) between amide and imidazole moieties achieves maximal activity.

  DOI：

  10.1021/jm00389a013

文献信息

• 3-heteroalkyl-2,4.quinzaoline-diones
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0293500A1

  公开（公告）日：1988-12-07

  A compound is described which is selected from the group consisting of those of the formula: wherein A is a divalent moiety of the formula: or and n is an integer from 2-10, inclusive; R is hydrogen, oxygen or alkyl having from one to four carbon atoms; Z is C or N; and when Z is N, --- is ――― and there is no R substituent, when Z is C and R is oxygen, --- is ―――; and when Z is C and R is alkyl, --- is ――― ; R6 is hydrogen or alkyl having from one to four carbon atoms; R1 and R2 may be the same or different and may be selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkoxy having from one to four carbon atoms, alkyl having from one to four carbon atoms, nitro and amino; wherein Heteroaryl is wherein R3 and R4 may be selected from hydrogen, alkyl having from one to four carbon atoms, or phenyl; and X is CH or N, together with the pharmaceutically acceptable salts thereof as well as a process for producing the same and its use for pharmaceutical processes.

  描述了一种化合物，所选自以下组合中的一种，其化学式为：其中A是化学式的二价基团：或者n为2-10之间的整数；R为氢、氧或具有1-4个碳原子的烷基；Z为C或N；当Z为N时，---为―――且没有R取代基，当Z为C且R为氧时，---为―――；当Z为C且R为烷基时，---为―――；R6为氢或具有1-4个碳原子的烷基；R1和R2可以相同也可以不同，可选自氢、卤素、三氟甲基、具有1-4个碳原子的烷氧基、具有1-4个碳原子的烷基、硝基和氨基；其中Heteroaryl为其中R3和R4可以选择自氢、具有1-4个碳原子的烷基或苯基；X为CH或N，以及其药学上可接受的盐，以及用于生产该化合物的过程及其在制药过程中的应用。
• N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0117462A2

  公开（公告）日：1984-09-05

  This disclosure describes novel N-[ω-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

  本公开介绍了新型 N-[ω-(1H-咪唑-1-基)烷基]芳基酰胺，它们具有抑制血栓素合成酶的特性，还可用于治疗高血压和心肌缺血。
• Omega-[(hetero)alkyl]benz[cd]indol-2-amines
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0230035A2

  公开（公告）日：1987-07-29

  Omega-[(hetero)alkyl]benz[cd]indol-2-amines useful in inhibition of thromboxane synthetase and in treatment of hypertension in warm-blooded animals are disclosed.

  公开了可用于抑制血栓素合成酶和治疗温血动物高血压的ω-[（杂）烷基]苯并[cd]吲哚-2-胺。
• HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Syros Pharmaceuticals, Inc.

  公开号：EP3057954A2

  公开（公告）日：2016-08-24
• HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Syros Pharmaceuticals, Inc.

  公开号：EP3057955A1

  公开（公告）日：2016-08-24